Verona Pharma Announces June 2025 Investor Conference Participation

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) has announced its participation in two major healthcare investor conferences in June 2025. The company's senior management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami. Webcasts of both presentations will be accessible through the Events and Presentations section on Verona Pharma's investor website.

05/21/2025 - 06:00 AM

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:

Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Time: 11:05 a.m. ET / 4:05 p.m. BST
Location: New York, NY

Goldman Sachs 46th Annual Global Healthcare Conference
Date: Monday, June 9, 2025
Time: 2:40 p.m. ET / 7:40 p.m. BST
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:


Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com
Wendy Ryan

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre^® (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

What investor conferences will Verona Pharma (VRNA) attend in June 2025?

Verona Pharma will participate in two conferences: the Jefferies Global Healthcare Conference on June 4, 2025, in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami.

When is Verona Pharma's presentation at the Jefferies Global Healthcare Conference 2025?

Verona Pharma will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET / 4:05 p.m. BST in New York.

How can investors access Verona Pharma's June 2025 conference presentations?

Investors can access webcasts of both conference presentations through the Events and Presentations link on the Investors page of Verona Pharma's website at www.veronapharma.com.